Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yannick Allanore

Showing results (291-300 of 448) with videos related to

Pageof 45
Sort By:
Clinical and Experimental Rheumatology|May 19, 2011
Association study of 3 rheumatoid arthritis risk loci in systemic sclerosis in European Caucasian populationBaptiste Coustet, Philippe Dieude, Julien Wipft, et al.
The Journal of Rheumatology|March 17, 2010
Phenotype-haplotype correlation of IRF5 in systemic sclerosis: role of 2 haplotypes in disease severityPhilippe Dieude, Karen Dawidowicz, Mickaël Guedj, et al.
Seminars in Arthritis and Rheumatism|February 6, 2025
Management of disease progression after autologous hematopoietic stem cell transplantation in systemic sclerosis: Results from an international questionnaire-based studyJulia Spierings, Giulia Bandini, Yannick Allanore, et al.
Annals of the Rheumatic Diseases|September 29, 2020
Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR databaseAnna-Maria Hoffmann-Vold, Yannick Allanore, Margarida Alves, et al.
The Lancet. Rheumatology|October 17, 2025
Exploiting a unified vascular framework to predict organ-specific complications and accomplish disease modification in systemic sclerosisJohn D Pauling, Yannick Allanore, Maya H Buch, et al.
Rheumatology (Oxford, England)|February 5, 2025
A phase 2 randomized trial of safety and pharmacokinetics of IgPro20 and IgPro10 in patients with diffuse cutaneous systemic sclerosisChristopher P Denton, Otylia Kowal-Bielecka, Susanna M Proudman, et al.
Arthritis Research & Therapy|April 17, 2015
Identification of NF-κB and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosisMaria Arismendi, Matthieu Giraud, Nadira Ruzehaji, et al.
Journal of Autoimmunity|June 26, 2026
High-intensity immunosuppression versus modern standard care in poor-prognosis diffuse cutaneous systemic sclerosis: A propensity-matched studyLucas Khellaf, Rémi Khellaf, Pierre Pinson, et al.
Arthritis Research & Therapy|February 1, 2018
Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR groupSabine Adler, Dörte Huscher, Elise Siegert, et al.
Arthritis Research & Therapy|May 20, 2015
A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) gene and systemic sclerosisRoberta Goncalves Marangoni, Benjamin D Korman, Yannick Allanore, et al.
Pageof 45

Showing results (291-300 of 448) with videos related to

Sort By:
Pageof 45
Clinical and Experimental Rheumatology|May 19, 2011
Association study of 3 rheumatoid arthritis risk loci in systemic sclerosis in European Caucasian populationBaptiste Coustet, Philippe Dieude, Julien Wipft, et al.
The Journal of Rheumatology|March 17, 2010
Phenotype-haplotype correlation of IRF5 in systemic sclerosis: role of 2 haplotypes in disease severityPhilippe Dieude, Karen Dawidowicz, Mickaël Guedj, et al.
Seminars in Arthritis and Rheumatism|February 6, 2025
Management of disease progression after autologous hematopoietic stem cell transplantation in systemic sclerosis: Results from an international questionnaire-based studyJulia Spierings, Giulia Bandini, Yannick Allanore, et al.
Annals of the Rheumatic Diseases|September 29, 2020
Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR databaseAnna-Maria Hoffmann-Vold, Yannick Allanore, Margarida Alves, et al.
The Lancet. Rheumatology|October 17, 2025
Exploiting a unified vascular framework to predict organ-specific complications and accomplish disease modification in systemic sclerosisJohn D Pauling, Yannick Allanore, Maya H Buch, et al.
Rheumatology (Oxford, England)|February 5, 2025
A phase 2 randomized trial of safety and pharmacokinetics of IgPro20 and IgPro10 in patients with diffuse cutaneous systemic sclerosisChristopher P Denton, Otylia Kowal-Bielecka, Susanna M Proudman, et al.
Arthritis Research & Therapy|April 17, 2015
Identification of NF-κB and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosisMaria Arismendi, Matthieu Giraud, Nadira Ruzehaji, et al.
Journal of Autoimmunity|June 26, 2026
High-intensity immunosuppression versus modern standard care in poor-prognosis diffuse cutaneous systemic sclerosis: A propensity-matched studyLucas Khellaf, Rémi Khellaf, Pierre Pinson, et al.
Arthritis Research & Therapy|February 1, 2018
Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR groupSabine Adler, Dörte Huscher, Elise Siegert, et al.
Arthritis Research & Therapy|May 20, 2015
A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) gene and systemic sclerosisRoberta Goncalves Marangoni, Benjamin D Korman, Yannick Allanore, et al.
Pageof 45